-
1
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.-R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
2
-
-
77955635233
-
Cancer Statistics, 2010
-
Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
3
-
-
0000524684
-
On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases
-
Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896, 2:105-107.
-
(1896)
Lancet
, vol.2
, pp. 105-107
-
-
Beatson, G.T.1
-
4
-
-
0001561849
-
Inhibition of human mammary and prostatic cancers by adrenalectomy
-
Huggins C., Berganstal D.M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res 1952, 12:134-141.
-
(1952)
Cancer Res
, vol.12
, pp. 134-141
-
-
Huggins, C.1
Berganstal, D.M.2
-
5
-
-
70449140922
-
Experiences with hypophysectomy in cancer of the breast
-
Olivecrona H., Luft R. Experiences with hypophysectomy in cancer of the breast. Ann R Coll Surg Eng 1957, 20:267-279.
-
(1957)
Ann R Coll Surg Eng
, vol.20
, pp. 267-279
-
-
Olivecrona, H.1
Luft, R.2
-
6
-
-
0013248993
-
The use of testosterone propionate in the treatment of advanced carcinoma of the breast
-
Adair F.E., Herrmann J.B. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 1946, 123:1023-1035.
-
(1946)
Ann Surg
, vol.123
, pp. 1023-1035
-
-
Adair, F.E.1
Herrmann, J.B.2
-
7
-
-
84873754102
-
Stilboestrol in late malignant disease of the breast
-
Rae I.P. Stilboestrol in late malignant disease of the breast. Glasgow Med J 1948, 29:248-254.
-
(1948)
Glasgow Med J
, vol.29
, pp. 248-254
-
-
Rae, I.P.1
-
8
-
-
0007831904
-
Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa
-
Greenspan E.M., Fieber M., Lesnick G., Edelman S. Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp 1963, 30:246-267.
-
(1963)
J Mt Sinai Hosp
, vol.30
, pp. 246-267
-
-
Greenspan, E.M.1
Fieber, M.2
Lesnick, G.3
Edelman, S.4
-
9
-
-
0017740963
-
Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group
-
Carter A.C., Sedransk N., Kelley R.M., et al. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977, 237:2079-2085.
-
(1977)
JAMA
, vol.237
, pp. 2079-2085
-
-
Carter, A.C.1
Sedransk, N.2
Kelley, R.M.3
-
10
-
-
75449149186
-
Cancer studies. Cancer of the breast.
-
Cline J.W. Cancer studies. Cancer of the breast. Cal Med 1963, 99:393-402.
-
(1963)
Cal Med
, vol.99
, pp. 393-402
-
-
Cline, J.W.1
-
11
-
-
0015069359
-
A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
-
Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25:270-275.
-
(1971)
Br J Cancer
, vol.25
, pp. 270-275
-
-
Cole, M.P.1
Jones, C.T.2
Todd, I.D.3
-
12
-
-
0032569831
-
Tamoxifen in the treatment of breast cancer
-
Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618.
-
(1998)
N Engl J Med
, vol.339
, pp. 1609-1618
-
-
Osborne, C.K.1
-
13
-
-
77955551055
-
American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
-
Burstein H.J., Prestrud A.A., Seidenfeld J., et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3784-3796
-
-
Burstein, H.J.1
Prestrud, A.A.2
Seidenfeld, J.3
-
14
-
-
0019382847
-
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
-
Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16-21.
-
(1981)
N Engl J Med
, vol.304
, pp. 16-21
-
-
Ingle, J.N.1
Ahmann, D.L.2
Green, S.J.3
-
15
-
-
0019236420
-
The tamoxifen trial a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer
-
Stewart H.J., Forrest A.P., Gunn J.M. The tamoxifen trial a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Eur J Cancer 1980, (Suppl 1):83-88.
-
(1980)
Eur J Cancer
, Issue.SUPPL. 1
, pp. 83-88
-
-
Stewart, H.J.1
Forrest, A.P.2
Gunn, J.M.3
-
16
-
-
0018900532
-
Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial
-
Westerberg H. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 1980, 64:117-121.
-
(1980)
Cancer Treat Rep
, vol.64
, pp. 117-121
-
-
Westerberg, H.1
-
17
-
-
0015915672
-
Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels
-
Ward H.W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973, 1:13-14.
-
(1973)
Br Med J
, vol.1
, pp. 13-14
-
-
Ward, H.W.1
-
18
-
-
0019167247
-
Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy
-
Manni A., Arafah B., Pearson O.H. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980, 46(Suppl 12):2838-2841.
-
(1980)
Cancer
, vol.46
, Issue.SUPPL. 12
, pp. 2838-2841
-
-
Manni, A.1
Arafah, B.2
Pearson, O.H.3
-
19
-
-
0035755679
-
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer
-
Fisher B., Jeong J.H., Dignam J., et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001, 62-66.
-
(2001)
J Natl Cancer Inst Monogr
, pp. 62-66
-
-
Fisher, B.1
Jeong, J.H.2
Dignam, J.3
-
20
-
-
0021918182
-
Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years.
-
The Nolvadex Adjuvant Trial Organisation
-
Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet 1985, 325:836-840. The Nolvadex Adjuvant Trial Organisation.
-
(1985)
Lancet
, vol.325
, pp. 836-840
-
-
-
21
-
-
0024506261
-
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
-
Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479-484.
-
(1989)
N Engl J Med
, vol.320
, pp. 479-484
-
-
Fisher, B.1
Costantino, J.2
Redmond, C.3
-
22
-
-
0032427758
-
Early stopping of a clinical trial when there is no evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project
-
Dignam J.J., Bryant J., Wieand H.S., Fisher B., Wolmark B. Early stopping of a clinical trial when there is no evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 1998, 19:575-588.
-
(1998)
Control Clin Trials
, vol.19
, pp. 575-588
-
-
Dignam, J.J.1
Bryant, J.2
Wieand, H.S.3
Fisher, B.4
Wolmark, B.5
-
23
-
-
0035795683
-
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial
-
Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst 2001, 93:684-690.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 684-690
-
-
Fisher, B.1
Dignam, J.2
Bryant, J.3
Wolmark, N.4
-
24
-
-
0026477124
-
The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group
-
Stewart H.J. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992, 117-120.
-
(1992)
J Natl Cancer Inst Monogr
, pp. 117-120
-
-
Stewart, H.J.1
-
25
-
-
0035925617
-
Scottish adjuvant tamoxifen trial: a randomized study updated to 15years
-
Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15years. J Natl Cancer Inst 2001, 93:456-462.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 456-462
-
-
Stewart, H.J.1
Prescott, R.J.2
Forrest, A.P.3
-
26
-
-
0019127362
-
Tamoxifen therapy in premenopausal patients with metastatic breast cancer
-
Pritchard K.I., Thomson D.B., Myers R.E., Sutherland D.J., Mobbs B.G., Meakin J.W. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 1980, 64:787-796.
-
(1980)
Cancer Treat Rep
, vol.64
, pp. 787-796
-
-
Pritchard, K.I.1
Thomson, D.B.2
Myers, R.E.3
Sutherland, D.J.4
Mobbs, B.G.5
Meakin, J.W.6
-
27
-
-
0022468199
-
Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma
-
Sawka C.A., Pritchard K.I., Paterson A.H., et al. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 1986, 46:3152-3156.
-
(1986)
Cancer Res
, vol.46
, pp. 3152-3156
-
-
Sawka, C.A.1
Pritchard, K.I.2
Paterson, A.H.3
-
28
-
-
0032537396
-
Tamoxifen for early breast cancer: an overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group
-
Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group.
-
(1998)
Lancet
, vol.351
, pp. 1451-1467
-
-
-
29
-
-
4944258278
-
Tamoxifen for early breast cancer (Cochrane Review)
-
Early Breast Cancer Trialists' Collaborative Group, The Cochrane Library, Chichester, UK
-
Tamoxifen for early breast cancer (Cochrane Review). The Cochrane Library 2004, 1-38. Early Breast Cancer Trialists' Collaborative Group, The Cochrane Library, Chichester, UK.
-
(2004)
The Cochrane Library
, pp. 1-38
-
-
-
30
-
-
40549132583
-
The risk of developing uterine sarcoma after tamoxifen use
-
Lavie O., Barnett-Griness O., Narod S.A., Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer 2008, 18:352-356.
-
(2008)
Int J Gynecol Cancer
, vol.18
, pp. 352-356
-
-
Lavie, O.1
Barnett-Griness, O.2
Narod, S.A.3
Rennert, G.4
-
31
-
-
0032537990
-
Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study
-
Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Costantino, J.P.2
Wickerham, D.L.3
-
32
-
-
80052059849
-
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
-
Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
-
(2002)
Lancet
, vol.360
, pp. 817-824
-
-
Cuzick, J.1
Forbes, J.2
Edwards, R.3
-
33
-
-
33847793068
-
Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial
-
Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 272-282
-
-
Cuzick, J.1
Forbes, J.F.2
Sestak, I.3
-
34
-
-
74849127916
-
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid
-
Fagerlin A., Zikmund-Fisher B.J., Nair V., et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 2010, 119:613-620.
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 613-620
-
-
Fagerlin, A.1
Zikmund-Fisher, B.J.2
Nair, V.3
-
35
-
-
77952569256
-
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
-
Lewis J.D., Chagpar A.B., Shaughnessey E.A., Nurko J., McMasters K., Edwards M.J. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010, 116:2307-2315.
-
(2010)
Cancer
, vol.116
, pp. 2307-2315
-
-
Lewis, J.D.1
Chagpar, A.B.2
Shaughnessey, E.A.3
Nurko, J.4
McMasters, K.5
Edwards, M.J.6
-
36
-
-
84877007293
-
-
Fareston summary of product characteristics. Available at <>[accessed 12.03.12
-
Fareston summary of product characteristics. Available at <>; 2010 [accessed 12.03.12. http://www.medicines.org.uk/emc/medicine/10221/SPC/Fareston+60mg+Tablets.
-
(2010)
-
-
-
37
-
-
10644283864
-
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
-
Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 1751-1761
-
-
Martino, S.1
Cauley, J.A.2
Barrett-Connor, E.3
-
38
-
-
0035687124
-
The MORE trial: multiple outcomes for raloxifen evaluation - breast cancer as a secondary end point: implications for prevention
-
Dickler M.N., Norton L. The MORE trial: multiple outcomes for raloxifen evaluation - breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 2001, 949:134-142.
-
(2001)
Ann N Y Acad Sci
, vol.949
, pp. 134-142
-
-
Dickler, M.N.1
Norton, L.2
-
39
-
-
33745249570
-
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
-
Vogel V.G., Constantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
-
(2006)
JAMA
, vol.295
, pp. 2727-2741
-
-
Vogel, V.G.1
Constantino, J.P.2
Wickerham, D.L.3
-
40
-
-
84876979537
-
-
Evista prescribing information. Available at <> [accessed 12.03.12].
-
Evista prescribing information. Available at <>; 2010 [accessed 12.03.12]. http://www.pi.lilly.com/us/evista-pi.pdf.
-
(2010)
-
-
-
41
-
-
77953529620
-
Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer
-
Vogel V.G., Constantino J.P., Wickerham D.L., et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696-706.
-
(2010)
Cancer Prev Res (Phila)
, vol.3
, pp. 696-706
-
-
Vogel, V.G.1
Constantino, J.P.2
Wickerham, D.L.3
-
43
-
-
38149063362
-
The role of ovarian ablation in the adjuvant therapy of breast cancer
-
Tan S.H., Wolff A.C. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep 2008, 10:27-37.
-
(2008)
Curr Oncol Rep
, vol.10
, pp. 27-37
-
-
Tan, S.H.1
Wolff, A.C.2
-
44
-
-
34748918347
-
Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference
-
Rabaglio M., Aebi S., Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 2007, 8:940-949.
-
(2007)
Lancet Oncol
, vol.8
, pp. 940-949
-
-
Rabaglio, M.1
Aebi, S.2
Castiglione-Gertsch, M.3
-
45
-
-
54749150299
-
Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings
-
McDonald Wade S., Hackney M.H., Khatcheressian J., Lyckholm L.J. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings. Oncology 2008, 75:192-202.
-
(2008)
Oncology
, vol.75
, pp. 192-202
-
-
McDonald Wade, S.1
Hackney, M.H.2
Khatcheressian, J.3
Lyckholm, L.J.4
-
46
-
-
33745308514
-
Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study
-
Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 2006, 42:895-904.
-
(2006)
Eur J Cancer
, vol.42
, pp. 895-904
-
-
Baum, M.1
Hackshaw, A.2
Houghton, J.3
-
47
-
-
62349124975
-
Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer
-
Hackshaw A., Baum M., Fornander T., et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009, 101:341-349.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 341-349
-
-
Hackshaw, A.1
Baum, M.2
Fornander, T.3
-
48
-
-
0037115422
-
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study
-
Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002, 20:4628-4635.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4628-4635
-
-
Jonat, W.1
Kaufmann, M.2
Sauerbrei, W.3
-
49
-
-
0042848736
-
Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer
-
Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003, 39:1711-1717.
-
(2003)
Eur J Cancer
, vol.39
, pp. 1711-1717
-
-
Kaufmann, M.1
Jonat, W.2
Blamey, R.3
-
50
-
-
34248574344
-
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials
-
Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
-
(2007)
Lancet
, vol.369
, pp. 1711-1723
-
-
Cuzick, J.1
Ambroisine, L.2
Davidson, N.3
-
51
-
-
80053151094
-
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
-
Karlsson P., Sun Z., Braun D., et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011, 22:2216-2226.
-
(2011)
Ann Oncol
, vol.22
, pp. 2216-2226
-
-
Karlsson, P.1
Sun, Z.2
Braun, D.3
-
52
-
-
50649113295
-
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
-
Miller W.R., Bartlett J., Brodie A.M., et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837.
-
(2008)
Oncologist
, vol.13
, pp. 829-837
-
-
Miller, W.R.1
Bartlett, J.2
Brodie, A.M.3
-
53
-
-
0020326760
-
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer
-
Harris A.L., Powles T.J., Smith I.E. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res 1982, 42(8 Suppl):3405s-3408s.
-
(1982)
Cancer Res
, vol.42
, Issue.8 SUPPL.
-
-
Harris, A.L.1
Powles, T.J.2
Smith, I.E.3
-
54
-
-
8944237006
-
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
-
Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996, 14:2000-2011.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2000-2011
-
-
Buzdar, A.1
Jonat, W.2
Howell, A.3
-
55
-
-
0032530988
-
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
-
Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
-
(1998)
Cancer
, vol.83
, pp. 1142-1152
-
-
Buzdar, A.U.1
Jonat, W.2
Howell, A.3
-
56
-
-
7344242595
-
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)
-
Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998, 9:639-645.
-
(1998)
Ann Oncol
, vol.9
, pp. 639-645
-
-
Gershanovich, M.1
Chaudri, H.A.2
Campos, D.3
-
57
-
-
0031943424
-
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
-
Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16:453-461.
-
(1998)
J Clin Oncol
, vol.16
, pp. 453-461
-
-
Dombernowsky, P.1
Smith, I.2
Falkson, G.3
-
58
-
-
0034669484
-
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
-
Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3758-3767
-
-
Nabholtz, J.M.1
Buzdar, A.2
Pollak, M.3
-
59
-
-
0034669435
-
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study
-
Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000, 18:3748-3757.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3748-3757
-
-
Bonneterre, J.1
Thürlimann, B.2
Robertson, J.F.3
-
60
-
-
0343584508
-
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group
-
Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2596-2606
-
-
Mouridsen, H.1
Gershanovich, M.2
Sun, Y.3
-
61
-
-
54449099359
-
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
-
Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4883-4890
-
-
Paridaens, R.J.1
Dirix, L.Y.2
Beex, L.V.3
-
62
-
-
33644550685
-
Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition
-
Gltick S. Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition. Biomed Pharmacother 2005, 59(Suppl 2):S321-S322.
-
(2005)
Biomed Pharmacother
, vol.59
, Issue.SUPPL. 2
-
-
Gltick, S.1
-
63
-
-
0037157603
-
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
-
The ATAC Trialists' Group
-
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. The ATAC Trialists' Group.
-
(2002)
Lancet
, vol.359
, pp. 2131-2139
-
-
-
64
-
-
11444251764
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
ATAC Trialists' Group
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. ATAC Trialists' Group.
-
(2005)
Lancet
, vol.365
, pp. 60-62
-
-
-
65
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
The Breast International Group (BIG) 1-98 Collaborative Group
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. The Breast International Group (BIG) 1-98 Collaborative Group.
-
(2005)
N Engl J Med
, vol.353
, pp. 2747-2757
-
-
-
66
-
-
10744223655
-
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
-
Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
-
(2004)
N Engl J Med
, vol.350
, pp. 1081-1092
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
-
67
-
-
78649603622
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
-
Cuzick J., Sestak I., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1135-1141
-
-
Cuzick, J.1
Sestak, I.2
Baum, M.3
-
68
-
-
69049113989
-
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
-
The BIG 1-98 Collaborative International Breast Cancer Study Group
-
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776. The BIG 1-98 Collaborative International Breast Cancer Study Group.
-
(2009)
N Engl J Med
, vol.361
, pp. 766-776
-
-
-
69
-
-
79952748821
-
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
-
Colleoni M., Giobbie-Hurder A., Regan M., et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1117-1124
-
-
Colleoni, M.1
Giobbie-Hurder, A.2
Regan, M.3
-
70
-
-
75749092296
-
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
-
Dowsett M., Cuzick J., Ingle J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
-
(2010)
J Clin Oncol
, vol.28
, pp. 509-518
-
-
Dowsett, M.1
Cuzick, J.2
Ingle, J.3
-
71
-
-
33745613829
-
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
-
Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl 7):vii10-vii14.
-
(2006)
Ann Oncol
, vol.17
, Issue.SUPPL. 7
, pp. 710-714
-
-
Boccardo, F.1
Rubagotti, A.2
Guglielmini, P.3
-
72
-
-
23444446523
-
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
-
Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.
-
(2005)
Lancet
, vol.366
, pp. 455-462
-
-
Jakesz, R.1
Jonat, W.2
Gnant, M.3
-
73
-
-
34447574894
-
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study
-
Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25:2664-2670.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2664-2670
-
-
Kaufmann, M.1
Jonat, W.2
Hilfrich, J.3
-
74
-
-
33751321384
-
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis
-
Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7:991-996.
-
(2006)
Lancet Oncol
, vol.7
, pp. 991-996
-
-
Jonat, W.1
Gnant, M.2
Boccardo, F.3
-
75
-
-
14544281511
-
BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor- positive breast cancer
-
BIG 1-98 Collaborative Group
-
BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor- positive breast cancer. The Breast 2005, 14(Suppl 1):S3. BIG 1-98 Collaborative Group.
-
(2005)
The Breast
, vol.14
, Issue.SUPPL. 1
-
-
-
76
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
77
-
-
24744450378
-
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
-
Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 1262-1271
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
-
78
-
-
38449107897
-
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast cancer and colorectal cancer study group trial 6a
-
Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast cancer and colorectal cancer study group trial 6a. J Natl Cancer Inst 2007, 99:1845-1853.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1845-1853
-
-
Jakesz, R.1
Greil, R.2
Gnant, M.3
-
79
-
-
42949104549
-
Benefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat.analysis of the national surgical adjuvant breast and bowel project B-33 trial
-
Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat.analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 2008, 26:1965-1971.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1965-1971
-
-
Mamounas, E.P.1
Jeong, J.H.2
Wickerham, D.L.3
-
80
-
-
0026395885
-
A potent specific pure antiestrogen with clinical potential
-
Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
-
(1991)
Cancer Res
, vol.51
, pp. 3867-3873
-
-
Wakeling, A.E.1
Dukes, M.2
Bowler, J.3
-
81
-
-
0037102121
-
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
-
Howell A., Robertson J.F.R., Quaresma J. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396-3403.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3396-3403
-
-
Howell, A.1
Robertson, J.F.R.2
Quaresma, J.3
-
82
-
-
42949144182
-
Tamoxifen and the uterus and endometrium
-
Cano A., Matallin P., Legua V., Tortajada M., Bonilla-Musoles F. Tamoxifen and the uterus and endometrium. Lancet 1989, 1:376.
-
(1989)
Lancet
, vol.1
, pp. 376
-
-
Cano, A.1
Matallin, P.2
Legua, V.3
Tortajada, M.4
Bonilla-Musoles, F.5
-
83
-
-
65649119341
-
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health
-
Ewer M.S., Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009, 115:1813-1826.
-
(2009)
Cancer
, vol.115
, pp. 1813-1826
-
-
Ewer, M.S.1
Glück, S.2
-
84
-
-
79951710902
-
Clinical review: effect of endocrine therapies on bone in breast cancer patients
-
Santen R.J. Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 2011, 96:308-319.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 308-319
-
-
Santen, R.J.1
-
85
-
-
0037102126
-
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial
-
Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386-3395.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3386-3395
-
-
Osborne, C.K.1
Pippen, J.2
Jones, S.E.3
-
86
-
-
0038683988
-
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
-
Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
-
(2003)
Cancer
, vol.98
, pp. 229-238
-
-
Robertson, J.F.1
Osborne, C.K.2
Howell, A.3
-
87
-
-
2442648038
-
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
-
Howell A., Robertson J.F.R., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1605-1613
-
-
Howell, A.1
Robertson, J.F.R.2
Abram, P.3
-
88
-
-
0028084758
-
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
-
DeFriend D.J., Howell A., Nicholson R.I., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994, 54:408-414.
-
(1994)
Cancer Res
, vol.54
, pp. 408-414
-
-
DeFriend, D.J.1
Howell, A.2
Nicholson, R.I.3
-
89
-
-
0035884408
-
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
-
Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001, 61:6739-6746.
-
(2001)
Cancer Res
, vol.61
, pp. 6739-6746
-
-
Robertson, J.F.1
Nicholson, R.I.2
Bundred, N.J.3
-
90
-
-
78049523306
-
Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
-
Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4594-4600
-
-
Di Leo, A.1
Jerusalem, G.2
Petruzelka, L.3
-
91
-
-
29244440841
-
Clinical trial update: international breast cancer study group
-
Price K.N., Goldhirsch A. Clinical trial update: international breast cancer study group. Breast Cancer Res 2005, 7:252-254.
-
(2005)
Breast Cancer Res
, vol.7
, pp. 252-254
-
-
Price, K.N.1
Goldhirsch, A.2
-
92
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
-
(2009)
N Engl J Med
, vol.360
, pp. 679-691
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
-
93
-
-
84866654068
-
ER and PI3K independently modulate endocrine resistance in ER positive breast cancer
-
Van Tine B.A., Crowder R.J., Ellis M.J. ER and PI3K independently modulate endocrine resistance in ER positive breast cancer. Cancer Discov 2011, 1:287-288.
-
(2011)
Cancer Discov
, vol.1
, pp. 287-288
-
-
Van Tine, B.A.1
Crowder, R.J.2
Ellis, M.J.3
-
94
-
-
84855364818
-
Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer
-
McCartan D., Bolger J., Fagan A., et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer. Cancer Res 2012, 72:220-229.
-
(2012)
Cancer Res
, vol.72
, pp. 220-229
-
-
McCartan, D.1
Bolger, J.2
Fagan, A.3
-
95
-
-
80054874720
-
Biological mechanisms and clinical implications of endocrine resistance in breast cancer
-
Giuliano M., Schifp R., Osborne C.K., Trivedi M.V. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011, 20(Suppl 3):S42-S49.
-
(2011)
Breast
, vol.20
, Issue.SUPPL. 3
-
-
Giuliano, M.1
Schifp, R.2
Osborne, C.K.3
Trivedi, M.V.4
-
96
-
-
84876996359
-
-
TAMRAD: A GINECO randomized Phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8-12 December (Abstract S1-6).
-
Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: A GINECO randomized Phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8-12 December, 2010 (Abstract S1-6).
-
(2010)
-
-
Bachelot, T.1
Bourgier, C.2
Cropet, C.3
-
97
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
-
(2012)
N Engl J Med
, vol.366
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
-
98
-
-
79551576468
-
Mechanisms of endocrine resistance in breast cancer
-
Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247.
-
(2011)
Annu Rev Med
, vol.62
, pp. 233-247
-
-
Osborne, C.K.1
Schiff, R.2
-
99
-
-
12144269500
-
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
-
Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11:865s-870s.
-
(2005)
Clin Cancer Res
, vol.11
-
-
Osborne, C.K.1
Shou, J.2
Massarweh, S.3
Schiff, R.4
-
100
-
-
80053341141
-
Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance
-
Emde A., Mahlknecht G., Maslak K., et al. Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance. Transl Oncol 2011, 4:293-300.
-
(2011)
Transl Oncol
, vol.4
, pp. 293-300
-
-
Emde, A.1
Mahlknecht, G.2
Maslak, K.3
-
101
-
-
82155187061
-
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
-
Wang Y.C., Morrison G., Gillihan R., et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011, 13:R121.
-
(2011)
Breast Cancer Res
, vol.13
-
-
Wang, Y.C.1
Morrison, G.2
Gillihan, R.3
-
102
-
-
77649100030
-
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer
-
Schwartzberg L.S., Franco S.X., Florance A., O'Rourke L., Maltzman J., Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15:122-129.
-
(2010)
Oncologist
, vol.15
, pp. 122-129
-
-
Schwartzberg, L.S.1
Franco, S.X.2
Florance, A.3
O'Rourke, L.4
Maltzman, J.5
Johnston, S.6
-
103
-
-
0034899503
-
Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells
-
Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001, 15:1344-1359.
-
(2001)
Mol Endocrinol
, vol.15
, pp. 1344-1359
-
-
Oh, A.S.1
Lorant, L.A.2
Holloway, J.N.3
Miller, D.L.4
Kern, F.G.5
El-Ashry, D.6
-
104
-
-
37249069903
-
Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response
-
Bayliss J., Hilger A., Vishnu P., Diehl K., El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007, 13:7029-7036.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 7029-7036
-
-
Bayliss, J.1
Hilger, A.2
Vishnu, P.3
Diehl, K.4
El-Ashry, D.5
-
105
-
-
80355135172
-
Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance
-
Trimarchi M.P., Mouangsavanh M., Huang T.H. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance. Chin J Cancer 2011, 30:749-756.
-
(2011)
Chin J Cancer
, vol.30
, pp. 749-756
-
-
Trimarchi, M.P.1
Mouangsavanh, M.2
Huang, T.H.3
-
106
-
-
75149159605
-
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
-
Wang L., Ellsworth K.A., Moon I., et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70:319-328.
-
(2010)
Cancer Res
, vol.70
, pp. 319-328
-
-
Wang, L.1
Ellsworth, K.A.2
Moon, I.3
-
107
-
-
84876996269
-
-
Cancer Research UK. Statistics and outlook for breast cancer. Available at <> [accessed 12.03.12].
-
Cancer Research UK. Statistics and outlook for breast cancer. Available at <>; 2011 [accessed 12.03.12]. http://www.cancerhelp.cancerresearchuk.org/type/breast-cancer/treatment/statistics-and-outlook-for-breast-cancer.
-
(2011)
-
-
|